Merck & Co. Adjustment for Amortization decreased by 4.3% to $931.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 55.9%, from $597.00M to $931.00M. Over 4 years (FY 2021 to FY 2025), Adjustment for Amortization shows an upward trend with a 14.3% CAGR.
Changes reflect shifts in acquisition accounting or valuation of intangible assets rather than operational performance.
This represents specific accounting adjustments made to amortization expenses, often related to intangible assets acquir...
Company-specific; peers may include this within 'Amortization of Intangibles' or 'Operating Expenses'.
gild_adjustment_for_amortization| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $357.00M | $360.00M | $405.00M | $699.00M | $464.00M | $460.00M | $462.00M | $543.00M | $477.00M | $562.00M | $462.00M | $473.00M | $614.00M | $633.00M | $675.00M | $597.00M | $601.00M | $622.00M | $973.00M | $931.00M |
| QoQ Change | — | +0.8% | +12.5% | +72.6% | -33.6% | -0.9% | +0.4% | +17.5% | -12.2% | +17.8% | -17.8% | +2.4% | +29.8% | +3.1% | +6.6% | -11.6% | +0.7% | +3.5% | +56.4% | -4.3% |
| YoY Change | — | — | — | — | +30.0% | +27.8% | +14.1% | -22.3% | +2.8% | +22.2% | +0.0% | -12.9% | +28.7% | +12.6% | +46.1% | +26.2% | -2.1% | -1.7% | +44.1% | +55.9% |
| Segment | Q1 '23 | Q3 '23 |
|---|---|---|
| Alliance revenue - Lenvima | $72.00M | $81.00M |
| Total | $543.00M | $562.00M |
Alliance revenue - Lenvima was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.